Loos U, Sörgel F, Marklein G, Kraeft H
Medizinische Universitätsklinik, Bonn.
Infection. 1989;17 Suppl 1:S23-4. doi: 10.1007/BF01643631.
We analysed enoxacin concentrations in plasma, saliva, bronchial secretions, bronchoalveolar lavage fluid, and alveolar macrophages in nine patients five hours after the last dose (400 mg enoxacin b.i.d. per os for at least three days). The enoxacin levels in the alveolar film were extrapolated from the lavage content by using urea as an internal marker (lavage dilution factor = plasma/lavage urea concentration ratio). The concentration in the alveolar film amounted to 7.62 mg/l ( = 381% of the plasma value), on average, and exceeded the minimal inhibitory concentrations of the pathogens isolated from the patients. Thus, enoxacin is effectively concentrated in the surface film of the lung which represents an important barrier against pulmonary infections.
我们分析了9名患者在最后一剂（口服400毫克依诺沙星，每日两次，至少持续三天）后5小时血浆、唾液、支气管分泌物、支气管肺泡灌洗液和肺泡巨噬细胞中的依诺沙星浓度。通过使用尿素作为内标，从灌洗内容物中推算出肺泡膜中的依诺沙星水平（灌洗稀释因子=血浆/灌洗尿素浓度比）。肺泡膜中的浓度平均为7.62毫克/升（=血浆值的381%），超过了从患者分离出的病原体的最低抑菌浓度。因此，依诺沙星有效地浓缩在肺的表面膜中，而肺表面膜是抵御肺部感染的重要屏障。
